Dr. Hao is the primary inventor or key contributor to numerous international patents and high-impact scientific publications. He previously established the biologics R&D team for Hansoh Pharma in the U.S., leading the project and platform development. He also served as the Chief Scientific Officer (CSO) and Senior Vice President (SVP) of Global Business Development and Marketing at a leading Chinese biopharmaceutical CDMO, where he successfully drove global business expansion and secured commercial licensing deals for CHO cell lines from multiple international institutions.
Most recently, Dr. Hao served as the Chief Scientific Officer at the Experimental Drug Development Centre (EDDC) in Singapore. In this role, he led strategic optimization of R&D directions, strengthened partnerships with Singapore’s academic research institutions and global pharmaceutical companies, and revamped project selection and evaluation criteria to improve the overall success rate of drug development programs.
Dr. Weidong Hao holds a bachelor's and master's degree in Biology from Tsinghua University, a Ph.D. in Microbiology and Molecular Genetics from the State University of New York at Stony Brook (SUNY Stony Brook), and an MBA from the Rady School of Management at the University of California, San Diego (UCSD).
郝卫东博士拥有清华大学生物学学士及硕士学位、纽约州立大学石溪分校（SUNY Stony Brook）微生物学与分子遗传学博士学位，以及加州大学圣地亚哥分校（UCSD, Rady School of Management）雷迪商学院的MBA学位。